REGENXBIO (NASDAQ:RGNX) Insider Sells 5,124 Shares

March 13, 2026 by InsiderTrades.com

Key Points

REGENXBIO missed its latest quarter, reporting EPS of -$1.30 vs. consensus -$1.01 and revenue of $30.34M vs. $45.48M, leaving negative margins and analyst forecasts around -4.84 EPS for the year.
Shares fell about 7.4% to $8.41 on heavy volume and are trading below their 50- and 200-day averages; insider Steve Pakola sold 5,124 shares (≈2% of his stake) at an average of $10.35.
The company faces increased headline and legal risk from multiple class-action filings and some bearish analyst commentary, even as REGENXBIO reported positive interim safety/efficacy signals for RGX‑202, creating mixed market sentiment.

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) insider Steve Pakola sold 5,124 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $10.35, for a total transaction of $53,033.40. Following the transaction, the insider owned 247,926 shares of the company's stock, valued at $2,566,034.10. This represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

REGENXBIO Trading Down 7.4%

RGNX traded down $0.68 during midday trading on Friday, hitting $8.41. 643,156 shares of the company were exchanged, compared to its average volume of 1,023,907. The company's 50 day simple moving average is $11.10 and its 200 day simple moving average is $11.43. The firm has a market capitalization of $433.78 million, a price-to-earnings ratio of -2.23 and a beta of 1.08. REGENXBIO Inc. has a 1-year low of $5.03 and a 1-year high of $16.19.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.29). REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%. The company had revenue of $30.34 million during the quarter, compared to analyst estimates of $45.48 million. On average, equities analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

Trending Headlines about REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

Positive Sentiment: Positive clinical data and safety signals for RGX‑202 from the Phase 1/2 AFFINITY Duchenne program — interim efficacy signals reported and company statements indicating no evidence of liver injury in the study, supporting the program's safety profile. AFFINITY interim data Safety: no liver injury
Neutral Sentiment: Insider transaction: Director/officer Steve Pakola sold 5,124 shares on March 10 at about $10.35 (disclosed 3/12). The sale is small (~2% reduction of his position) but attracts attention given current volatility. SEC filing
Neutral Sentiment: Market reaction described as "mixed signals" by coverage — clinical progress noted but shares have moved downward amid other news flow. This commentary helps explain intraday weakness. Benzinga: mixed signals
Negative Sentiment: Multiple law firms have filed or are soliciting class-action claims against REGENXBIO for alleged securities violations covering purchases from Feb. 9, 2022 to Jan. 27, 2026, and are seeking lead plaintiffs (April 14, 2026 deadline). The proliferation of filings increases potential legal/settlement risk and creates headline pressure. GlobeNewswire: Schall Law Firm
Negative Sentiment: Analyst headwind: HC Wainwright published a bearish forecast for RGNX Q1 earnings, adding downward pressure from the sell-side amid already-missed revenue/EPS guidance in recent quarters. Analyst negativity can amplify selling when combined with legal headlines. HC Wainwright forecast

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on RGNX. Barclays began coverage on shares of REGENXBIO in a research note on Tuesday, January 27th. They set an "overweight" rating and a $37.00 price objective on the stock. Leerink Partners boosted their target price on shares of REGENXBIO from $16.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, December 15th. Wall Street Zen cut REGENXBIO from a "hold" rating to a "sell" rating in a research report on Saturday, January 31st. UBS Group reaffirmed an "overweight" rating and set a $18.00 target price on shares of REGENXBIO in a research note on Tuesday, February 10th. Finally, Stifel Nicolaus lifted their price target on shares of REGENXBIO from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Friday, December 19th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, REGENXBIO has a consensus rating of "Moderate Buy" and an average target price of $27.50.

Check Out Our Latest Research Report on RGNX

Hedge Funds Weigh In On REGENXBIO

Several hedge funds and other institutional investors have recently made changes to their positions in RGNX. JPMorgan Chase & Co. raised its stake in REGENXBIO by 4.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,037,248 shares of the biotechnology company's stock valued at $38,959,000 after purchasing an additional 185,223 shares during the last quarter. Vanguard Group Inc. boosted its stake in REGENXBIO by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,374,140 shares of the biotechnology company's stock worth $48,588,000 after purchasing an additional 36,042 shares during the last quarter. State Street Corp grew its holdings in shares of REGENXBIO by 15.2% during the fourth quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company's stock worth $32,929,000 after buying an additional 301,858 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of REGENXBIO by 5.6% during the fourth quarter. AQR Capital Management LLC now owns 1,361,962 shares of the biotechnology company's stock worth $19,612,000 after buying an additional 72,307 shares in the last quarter. Finally, Integral Health Asset Management LLC raised its position in shares of REGENXBIO by 9.1% in the fourth quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the biotechnology company's stock valued at $17,280,000 after buying an additional 100,000 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company's stock.

About REGENXBIO

(Get Free Report)

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO's pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.